Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer

Rydhög, Jonas Scherman ; Mortensen, Steen Riisgaard ; Larsen, Klaus Richter ; Clementsen, Paul ; Jølck, Rasmus Irming ; Josipovic, Mirjana ; Aznar, Marianne Camille ; Specht, Lena ; Andresen, Thomas Lars and Rosenschöld, Per Munck af LU orcid , et al. (2016) In Radiotherapy and Oncology 121(1). p.64-69
Abstract

Background and purpose We analysed the positional and structural stability of a long-term biodegradable liquid fiducial marker (BioXmark) for radiotherapy in patients with locally advanced lung cancer. Material and methods Markers were injected via endoscopic- or endobronchial ultrasound in lymph nodes and reachable primary tumours. Marker volume and Hounsfield Units (HU) changing rates were estimated using breath-hold CBCT. Inter-fraction variation in marker position relative to gross tumour volume (GTV) position was established, as well as the inter-fraction variation in mediastinal marker registration relative to a carina registration through the treatment. Results Fifteen patients were included and 29 markers analysed. All markers... (More)

Background and purpose We analysed the positional and structural stability of a long-term biodegradable liquid fiducial marker (BioXmark) for radiotherapy in patients with locally advanced lung cancer. Material and methods Markers were injected via endoscopic- or endobronchial ultrasound in lymph nodes and reachable primary tumours. Marker volume and Hounsfield Units (HU) changing rates were estimated using breath-hold CBCT. Inter-fraction variation in marker position relative to gross tumour volume (GTV) position was established, as well as the inter-fraction variation in mediastinal marker registration relative to a carina registration through the treatment. Results Fifteen patients were included and 29 markers analysed. All markers that were in situ at planning were visible through the treatment. Mean HU was 902 ± 165 HU for lymph node and 991 ± 219 HU for tumour markers. Volume degradation rates were −5% in lymph nodes and −23% in primary tumours. Three-dimensional inter-fraction variation for marker position relative to the GTV position was −0.1 ± 0.7 mm in lymph nodes and −1.5 ± 2.3 mm in primary tumours. Inter-fraction variations in marker registration relative to carina registration were −0.4 ± 1.2 mm in left–right, 0.2 ± 2.0 mm in anterior–posterior and −0.5 ± 2.0 mm in cranio-caudal directions. Conclusions The liquid fiducial markers were visible and stable in size and position throughout the treatment course.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Image-guided radiotherapy, Liquid fiducial marker, Marker visibility, NSCLC
in
Radiotherapy and Oncology
volume
121
issue
1
pages
64 - 69
publisher
Elsevier
external identifiers
  • pmid:27443450
  • scopus:84992648108
ISSN
0167-8140
DOI
10.1016/j.radonc.2016.06.012
language
English
LU publication?
no
additional info
Publisher Copyright: © 2016 Elsevier Ireland Ltd
id
13397837-65c7-402a-a7c4-81c21c517c31
date added to LUP
2023-07-31 13:37:15
date last changed
2024-02-19 22:00:03
@article{13397837-65c7-402a-a7c4-81c21c517c31,
  abstract     = {{<p>Background and purpose We analysed the positional and structural stability of a long-term biodegradable liquid fiducial marker (BioXmark) for radiotherapy in patients with locally advanced lung cancer. Material and methods Markers were injected via endoscopic- or endobronchial ultrasound in lymph nodes and reachable primary tumours. Marker volume and Hounsfield Units (HU) changing rates were estimated using breath-hold CBCT. Inter-fraction variation in marker position relative to gross tumour volume (GTV) position was established, as well as the inter-fraction variation in mediastinal marker registration relative to a carina registration through the treatment. Results Fifteen patients were included and 29 markers analysed. All markers that were in situ at planning were visible through the treatment. Mean HU was 902 ± 165 HU for lymph node and 991 ± 219 HU for tumour markers. Volume degradation rates were −5% in lymph nodes and −23% in primary tumours. Three-dimensional inter-fraction variation for marker position relative to the GTV position was −0.1 ± 0.7 mm in lymph nodes and −1.5 ± 2.3 mm in primary tumours. Inter-fraction variations in marker registration relative to carina registration were −0.4 ± 1.2 mm in left–right, 0.2 ± 2.0 mm in anterior–posterior and −0.5 ± 2.0 mm in cranio-caudal directions. Conclusions The liquid fiducial markers were visible and stable in size and position throughout the treatment course.</p>}},
  author       = {{Rydhög, Jonas Scherman and Mortensen, Steen Riisgaard and Larsen, Klaus Richter and Clementsen, Paul and Jølck, Rasmus Irming and Josipovic, Mirjana and Aznar, Marianne Camille and Specht, Lena and Andresen, Thomas Lars and Rosenschöld, Per Munck af and Persson, Gitte Fredberg}},
  issn         = {{0167-8140}},
  keywords     = {{Image-guided radiotherapy; Liquid fiducial marker; Marker visibility; NSCLC}},
  language     = {{eng}},
  month        = {{10}},
  number       = {{1}},
  pages        = {{64--69}},
  publisher    = {{Elsevier}},
  series       = {{Radiotherapy and Oncology}},
  title        = {{Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer}},
  url          = {{http://dx.doi.org/10.1016/j.radonc.2016.06.012}},
  doi          = {{10.1016/j.radonc.2016.06.012}},
  volume       = {{121}},
  year         = {{2016}},
}